8.3 C
New York
Monday, January 30, 2023

Don't miss

Drug slows Alzheimer’s cognitive decline, study finds

- Advertisement -

The material was released this Wednesday, 30, by the New England Journal Of Medicine; results also showed important and negative side effects in patients


- Advertisement -

In all, 1,800 people participated in the test, which lasted 18 months and whose results were released this Wednesday.

Scientists celebrated the results of a clinical trial which proved that a damn it delays cognitive decline in patients with Alzheimer’s, in addition to pointing out important side effects. The material was released on Wednesday, 30, by the New England Journal Of Medicine. The results of the advanced clinical trial carried out with 1,800 people for a year and a half showed a 27% reduction in cognitive impairment in patients who received lecanemab, a drug developed by the Japanese group Eisai and the American company Biogen. However, the results also point to side effects, sometimes serious.

- Advertisement -

In total, 17.3% of patients who received the drug experienced brain hemorrhages, compared with 9% of the placebo group. Furthermore, 12.6% of the patients had cerebral edema, against only 1.7% of the placebo group. The mortality rate was almost the same in both groups: 0.7% in those who received the drug and 0.8% in those who received a placebo. “It’s the first medicine that offers a real treatment option for people with Alzheimer’s,” said Bart De Strooper, director of the British Institute for Dementia Research. “While the clinical benefits seem somewhat limited, it is expected that they will become more evident if the drug is given over a longer period of time,” he said.

­čçž­čçĚWith information from AFP

Source: Jovempan

- Advertisement -

Latest Posts